CKD3 Summit on March 17-19, 2025 in Boston, United States

The transformative era of kidney drug development is here, with 2024 bringing landmark advancements, including Novartis' Borealis Biosciences and approvals in IgAN, Travere Therapeutics, and industry-defining acquisitions by Biogen and Vertex. Breakthrough therapies like SGLT2 inhibitors, GLP-1s, and MRAs continue to reshape the CKD treatment paradigm, while the FDA's accelerated pathways fuel unprecedented innovation. We are witnessing a renaissance in chronic kidney disease research and development and treatment.

The 7th CKD Drug Development Summit returns in 2025 as the definitive forum for connecting industry leaders, KOLs, researchers, and regulators. Addressing the most pressing challenges across renal research and development, this event serves as the unrivaled platform to share breakthroughs, inspire collaboration, and advance strategies for improving clinical outcomes in renal care all to bring better drugs to patients faster.

URLs:

Tickets: https://go.evvnt.com/2763582-2?pid=10008

Brochure: https://go.evvnt.com/2763582-3?pid=10008

Prices:
Conference + Workshop Day OR Focus Day - Primary: USD 4896.00,
Conference Only - Primary: USD 3099.00,
Conference + Workshop Day OR Focus Day - Discounted: USD 4196.00,
Conference Only - Discounted: USD 2699.00,
Conference + Workshop Day OR Focus Day - Vendor: USD 5896.00,
Conference Only - Vendor: USD 3799.00

Speakers: Aliza Thompson, Deputy Director of the Division of Cardiology and Nephrology, US Food and Drug Administration , Amit Sharma, Executive Vice President, Vera Therapeutics, Denis Feliers, Research Fellow, Pfizer, Dominik Steubl, Senior Leader, Clinical Program, Boehringer Ingelheim, Hiddo Heerspink, Adjunct Professor, Clinical Pharmacologist, University of Gronigan, Jonathan Barratt, Professor, Renal Medicine and Consultant Nephrologist, University of Leicester, Pernille Laerkegaard Hansen, Executive Director and Head of Bioscience and Renal, AstraZeneca, Julie Lin, Global Project Head, Sanofi, Manish Maski, Executive Director, Global Medical Affairs and Nephrology Lead, Vertex Pharmaceuticals, Uptal Patel, President, Founder and Chief Executive Officer, HIBio, Lisette Koeneman, Associate Vice President, Lilly Diabetes Global Medical Affairs, BI-LLY Alliance, Eli Lilly and Co., Moshe Vardi, Vice President, Research and Development, Cardiovascular and Renal, CSL Behring, Brian Pereira, President and Chief Executive Officer, Board Member, Visterra , Carol Moreno Quinn, Head of Immunology, Infectious Diseases, Cardiovascular, Renal and Metabolism, Global Medical Affairs, Roche, Alix Berton, Vice President and Head of Translational Sciences Cardiovascular Renal Immunology, Bayer, Robert Perkins, Vice President, Renal and Cardiovascular Medical Affairs, Bayer, Dustin Little, Renal and Global Clinical Lead, AstraZeneca, Angela Hu, Clinical Research Director, Rare Disorders, Sanofi, Joshua Tarnoff, Chief Executive Officer, NephCure Kidney International, Li Li, Senior Medical Director, Apellis Pharmaceuticals, Charles Lee, Executive Director, Regulatory Affairs, Cardiovascular, Renal and Metabolism, AstraZeneca, Moin Saleem, Founder and Scientific Chief and Advisor, Purespring Therapeutics, Matthew Breyer, Former, Distingushed Scientist, Johnson and Johnson Services, Radko Komers, Senior Director, Nephrology and Medical, Travere Therapeutics, Savithri Kota, Director, Precision Nephrology, Bayer, Rowland Elwell, Head of Field Medical Affairs, Calliditas Therapeutics, Preston Klassen, President, Head of Research and Development, Regulus Therapeutics, Pamela Winterberg, Senior Director, Medical, Alexion Pharmaceuticals, Alfica Sehgal, Chief Scientific Officer, Judo Bio, Alex Bell, Senior Director, Translation Biology and Strategic Alignment, Borealis Biosciences, Ralph Gruber, Principal Scientist, Lab Head, Project Team Leader, Novartis, Alice Brown, Chief Scientific Officer, Purespring Therapeutics, Vivek Das, Senior Research Scientist, Novo Nordisk, Simone Romoli, Senior Principal Scientist, Pfizer, Susan Thomas, Early Assets Medical Lead, GSK, Richard George, Executive Director, Global Medical Development, Regeneron Pharmaceuticals, Matthias Kretzler, Professor, Medicine, University of Michigan, Laura Mariani, Nephrologist, University of Michigan, Tobias B Huber, Director, Medicine, Science, Nephrology, Glomerular Disease, Global Networking and Discovery, Universit Sklinikum Hamburg-Eppendorf, Hiddo Heerspink, Adjunct Professor, Clinical Pharmacologist, Rijksuniversiteit Groningen, Dana Rizk, Professor, Medicine, University of Alabama at Birmingham, Peter Rossing, Senior Principal Investigator, Steno Diabetes Center Copenhagen, Benjamin Freedman, Associate Professor, Medicine, Institute Of Translational Health Sciences , Sagar Nigwekar, Associate Director, Global Clinical Scholars Research Training and Program, Harvard Medical School, David Wheeler, Professor, Kidney Medicine, Univeristy College London

Time: 08:00 to 18:00